Physician profile
Diana Hoppe
NPI 1114944618
$67,688.19
in general payments reported to CMS, 2019-2025
22 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $184 · 2021: $2,553 · 2022: $406 · 2023: $36K · 2024: $27K · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Travel and Lodging: $4,475 · Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,982.50 |
| Travel and Lodging | $4,475.25 |
| Food and Beverage | $1,493.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $63,893.88 | 2023-2025 | Veozah |
| Evofem Biosciences, INC. | $1,655.49 | 2021-2022 | |
| Lupin INC. | $600.00 | 2021 | |
| Therapeuticsmd, INC. | $344.50 | 2019-2022 | |
| Allergan, INC. | $215.16 | 2019-2020 | |
| Abbvie INC. | $159.27 | 2020-2022 | |
| Amgen INC. | $134.23 | 2019 | |
| Myovant Sciences INC. | $108.42 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $80.24 | 2022 | |
| Eisai INC. | $69.07 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $65.78 | 2021-2022 | |
| Becton, Dickinson and Company | $61.08 | 2021-2022 | |
| Revance Therapeutics, INC. | $57.76 | 2024 | Daxxify |
| Vertical Pharmaceuticals, LLC | $45.93 | 2019 | |
| Merck Sharp & Dohme LLC | $37.53 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $37.20 | 2022 | |
| Avion Pharmaceuticals | $29.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $22.35 | 2019 | |
| Coopersurgical, INC. | $20.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.12 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.78 | 2019 | |
| Acella Pharmaceuticals, LLC | $15.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Hoppe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.